Please assess the completion status of the following clinical trial:

Trial Title: A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Parts A, B, C, and D: 60 years of age or older~* Treatment-naive patients with histopathological diagnosis of classical Hodgkin lymphoma (Parts A, B, C, D, and E)~* Treatment-naive patients with CD30-expressing PTCL (Part F)~* Ineligible for or have declined initial conventional combination chemotherapy for HL (Parts A, B, C, and D)~* Unsuitable or unfit for initial conventional combination chemotherapy for HL (Part E) or CD30-expressing PTCL due to the presence of comorbidity-factors, as documented by:~  * A CIRS score of 10 or greater~ * Requiring assistance with or dependence on other for any instrumental activities of daily living (IADLs)~* Measurable disease of at least 1.5 cm as documented by radiographic technique~* Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 3 (Parts, A, B, C, E, and F) or less than or equal to 2 (Part D)~Exclusion Criteria:~* Symptomatic neurologic disease compromising IADLs or requiring medication~* History of progressive multifocal leukoencephalopathy~* Grade 3 or higher viral, bacterial, or fungal infection within 2 weeks prior to the first dose of brentuximab vedotin~* Concurrent use of other investigational agents~* Chemotherapy, radiotherapy, biologics, and/or other treatment with immunotherapy not completed 4 weeks prior to first dose of study drug~* History of another malignancy within 1 year before first dose of study drug (Parts E and F only)~* Part D only:~  * Received any prior immune-oncology therapy~ * History of known or suspected autoimmune disease~ * Prior allogeneic stem cell transplant~ * History of cerebral vascular event within 6 months of first dose of study drug~ * Active interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicology~ * Known history of pancreatitis~* Parts D, E, and F only:~  * Known cerebral/meningeal disease related to the underlying malignancy~ * Systemic treatment with corticosteroids or other immunosuppressive medications within 1 week of enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part A: Brentuximab Vedotin in HL Patients (Type: EXPERIMENTAL): None
- Part B: Brentuximab Vedotin + Dacarbazine in HL Patients (Type: EXPERIMENTAL): None
- Part C: Brentuximab Vedotin + Bendamustine in HL Patients (Type: EXPERIMENTAL): None
- Part D: Brentuximab Vedotin + Nivolumab in HL Patients (Type: EXPERIMENTAL): None
- Part E: Brentuximab Vedotin in HL Patients (Type: EXPERIMENTAL): None
- Part F: Brentuximab Vedotin in PTCL Patients (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).